Search Results

88 percent of transplant-eligible patients achieved a complete response or better, and 47 percent of patients sustained MRD-negativity for longer than one year with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based induction, consolidation and maintenance regimens in the Phase 3 PERSEUS study 7.5 years median overall survival achieved with DARZALEX®-based regimen in Phase 3 MAIA final analysis is the longest reported in patients ineligible for transplant

Significantly lower infusion-related reactions seen with subcutaneous amivantamab compared with intravenous administration in new Phase 2 data

New MajesTEC-1 data show a median duration of response of 24 months, with responses deepening, including in patients who switched to biweekly dosing1 Separate analyses from the MajesTEC-1 and OPTec studies are the first to underscore the opportunity for outpatient administration of TECVAYLI®

New formulation showed non-inferiority to intravenous administration in fourth positive Phase 3 study in RYBREVANT® clinical program Longer overall survival, progression-free survival and duration of response shown with subcutaneous amivantamab; featured in Best of ASCO 2024 RYBREVANT® marketing application submitted to European Medicines Agency based on PALOMA-3 study

Investigational chemotherapy-free regimen of RYBREVANT® plus lazertinib addresses a significant unmet need as most patients with EGFR-mutated NSCLC have high-risk disease Landmark Phase 3 MARIPOSA data featured in an oral presentation at ASCO

Strengthens Position in Highest-Growth, Innovation-Oriented Segments of Cardiovascular Intervention Creates Greater Opportunity to Transform the Treatment Landscape for Cardiovascular Disease

Meet Xiao-Yu Song, Global Head of Research & Development for Vision at Johnson & Johnson, who leads a talented team that creates cutting-edge products addressing vision problems through all stages of life.

Seltorexant, an investigational first-in-class therapy, met all primary and secondary endpoints in pivotal Phase 3 study in patients with major depressive disorder (MDD) with insomnia symptoms, as presented at ASCP 2024 Approximately 60 percent of MDD patients on standard-of-care oral antidepressants experience residual insomnia symptoms1, underscoring the high level of unmet need Positive topline results for SPRAVATO® (esketamine) CIII nasal spray as a monotherapy were also presented, demonstrating rapid and sustained efficacy in treatment-resistant depression (TRD)

The Company1 enters agreement with Numab Therapeutics to acquire its wholly owned subsidiary2 for the global rights to NM26, a Phase 2-ready investigational, first-in-class bispecific antibody targeting two clinically proven pathways in atopic dermatitis (AD) NM26 has the potential to offer distinctive benefits versus existing treatments and address key unmet needs for AD patients Johnson & Johnson is committed to developing differentiated bispecific antibodies for treating AD and other immune-mediated diseases